PURE Bioscience (OTCMKTS:PURE – Get Free Report) and ARQ (NASDAQ:ARQ – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for PURE Bioscience and ARQ, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
PURE Bioscience | 0 | 0 | 0 | 0 | N/A |
ARQ | 0 | 0 | 0 | 0 | N/A |
Institutional and Insider Ownership
Earnings & Valuation
This table compares PURE Bioscience and ARQ’s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
PURE Bioscience | $1.87 million | 4.50 | -$3.96 million | ($0.06) | -1.25 |
ARQ | $99.18 million | 2.14 | -$12.25 million | ($0.27) | -21.78 |
PURE Bioscience has higher earnings, but lower revenue than ARQ. ARQ is trading at a lower price-to-earnings ratio than PURE Bioscience, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
PURE Bioscience has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, ARQ has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
Profitability
This table compares PURE Bioscience and ARQ’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
PURE Bioscience | -191.92% | -717.03% | -330.11% |
ARQ | -8.15% | -4.65% | -3.51% |
Summary
ARQ beats PURE Bioscience on 6 of the 11 factors compared between the two stocks.
About PURE Bioscience
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.
About ARQ
Arq, Inc. produces activated carbon products in North America. The company's products include granular activated carbon, powdered and granular activated carbon, and colloidal carbon products; Arq Powder Wetcake, a fine and low-ash coal waste-derived particle; and additives for air emissions control. Its products are used in various applications, including water treatment, ground water remediation, soil sediments, air emissions, and asphalt additives. The company was formerly known as Advanced Emissions Solutions, Inc. and changed its name to Arq, Inc. in February 2024. Arq, Inc. was founded in 1997 and is headquartered in Greenwood Village, Colorado.
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.